Sangamo showcases progress in our pre-clinical programs at ASGCT.

Board of Directors

Courtney Beers, Ph.D.

Chief Scientific Officer at Tizona Therapeutics, Inc.

Courtney Beers, Ph.D., has served as a member of our Board of Directors since December 2022. Dr. Beers has served as the Chief Scientific Officer at Tizona Therapeutics, Inc., a privately held biotechnology company, since June 2019, bringing to the role 30 years of experience in immunology and cancer research, drug development and scientific strategy and leadership. She joined Tizona in 2015 to build the pipeline and research team needed to advance work critical to the company’s strategy. During Dr. Beers’ tenure, the company has advanced two Tizona–generated, first-in-class therapeutics into the clinic while also building an innovative portfolio of programs with the goal of positively impacting the lives of cancer patients. Prior to joining Tizona, Dr. Beers was the Head of Cancer Immunotherapy at Oncothyreon, Inc., where she spearheaded several novel immune-modulatory biologic programs. In addition, she held roles of increasing responsibility at Amgen Inc. and Immunex Corporation in the Therapeutic Innovation Unit, as well as the Oncology Discovery Research. Her immuno-oncology research resulted in multiple discovery programs and contributed to Amgen immunotherapy strategy and product pipeline. Dr. Beers was the Global Research Lead for Imlygic® (talimogene laherparepvec), the first oncolytic viral immunotherapy to win FDA approval. She also led Amgen’s AMG 228 program from inception to Phase 1 clinical trials. Courtney earned her Ph.D. in Immunology from the University of Washington.